Literature DB >> 7701245

The natural course of peptic ulcer disease and its predictors.

H Petersen1, P Kristensen, T Johannessen, P M Kleveland, J H Dybdahl, H Myrvold.   

Abstract

BACKGROUND: Little is known about today's natural course of peptic ulcer disease (PUD).
METHODS: A follow-up study based on a structured telephone interview was attempted in 728 patients with an endoscopic diagnosis of peptic ulcer in 1980-84.
RESULTS: Seven patients (1%) died because of PUD during the 8- to 10-year follow-up period. Of the 441 interviewed patients 15.2% had experienced no further clinical manifestations of PUD, 10.9% had had bleeding and 0.7% perforation, and 17.5% had been operated on. The operated patients reported fewer symptoms (p < 0.01) during the last 2 weeks before the interview than those not operated on. On an average the unoperated patients had had symptoms and had used histamine-2-receptor antagonists (H2RA) 12 and 10 weeks per year, respectively. Long-term treatment with H2RA was reported by 18%. More than one-third (36%) of the unoperated patients stated that the symptoms had had a significant negative impact on their lives. Age at onset of disease and index ulcer, family history, use of anti-inflammatory drugs and alcohol, bleeding, and another chronic disease were found to be significant predictors of the course.
CONCLUSION: In more than one-third of the patients with PUD the course is still burdened with many symptoms and complications.

Entities:  

Mesh:

Year:  1995        PMID: 7701245     DOI: 10.3109/00365529509093230

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  2 in total

Review 1.  Therapy and prevention of gastric ulcer.

Authors:  C B Lamers; I Biemond; A A Masclee; R A Veenendaal
Journal:  Yale J Biol Med       Date:  1996 May-Jun

2.  An economic model of long-term use of celecoxib in patients with osteoarthritis.

Authors:  Michael Loyd; Dale Rublee; Philip Jacobs
Journal:  BMC Gastroenterol       Date:  2007-07-04       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.